DPPOS AD/ADRD Health Economics Evaluation

DPPOS AD/ADRD 健康经济学评估

• 批准号: 10702144
• 负责人: Jose Alejandro Luchsinger
• 金额: $ 25万
• 依托单位: COLUMBIA UNIVERSITY HEALTH SCIENCES
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-01 至 2027-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10702144
• 关键词: Alzheimer' s disease related dementia; Caregivers; Caring; Cost utility; Data; Economics; Effectiveness; Exercise; Health; Health Care Costs; Health Care Sector; Intervention; Life Style; Medical; Medical Care Costs; Medicine; Metformin; Outcome; Participant; Placebos; Productivity; Randomized; Resources; Time; base; cost; cost effectiveness; cost-effectiveness evaluation; economic evaluation; health economics; intervention cost; mortality; simulation

With this supplemental request, in DPPOS AD/ADRD during 2022-2027, we propose to extend our previous analyses to evaluate the longer-term cost-utility and cost-effectiveness of the three original DPP interventions by incorporating additional data on resource utilization, costs, health states/status, health utilities, and mortality. To support these economic analyses, we will continue to collect information on resource utilization and costs associated with the interventions and with medical care outside the study, and information on health outcomes, health utilities, and survival. Based on the resource utilization and cost data collected during DPP/DPPOS, we will summarize the total healthcare costs associated with each of the three original DPP randomized interventions. As recommended by the Second Panel on Cost-Effectiveness in Health and Medicine (3), healthcare costs will include costs in the formal healthcare sector (e.g., costs associated with implementing and maintaining the DPP/DPPOS interventions, and costs of medical care outside the study), those in the informal healthcare sector (e.g., costs of time spent by participants on exercising and costs of time spent by caregivers), and those in the non-healthcare sector (e.g., costs arising from lost productivity). We will estimate the mean per capita healthcare costs associated with each of the three original DPP randomized interventions over the time course of DPP/DPPOS, and calculate the incremental healthcare costs of the ILS and MET interventions relative to placebo and each other from a healthcare sector perspective and a societal perspective.

通过这一补充请求，在2022-2027年期间的DPPOS AD/ADRD中，我们建议延长我们的 以前的分析，以评估长期的成本效用和成本效益的三个原来的 通过纳入关于资源利用、费用、健康状况/状况的额外数据， 健康效用和死亡率。为了支持这些经济分析，我们将继续收集 与干预措施和医疗护理相关的资源利用和成本信息 研究之外，以及关于健康结果、健康效用和生存率的信息。基于 在DPP/DPPOS期间收集的资源利用和成本数据，我们将汇总 与三种原始DPP随机干预相关的医疗保健成本。作为 根据第二个卫生和医药成本效益小组的建议（3）， 将包括正规医疗保健部门的费用（例如，与执行和 维持DPP/DPPOS干预措施，以及研究外的医疗费用）， 非正规保健部门（例如，参与者锻炼所花费的时间成本和时间成本 护理人员花费的费用），以及非医疗保健部门的费用（例如，生产力的损失）。 我们将估计与三个原始DPP中的每一个相关的人均医疗保健成本 在DPP/DPPOS的时间过程中随机干预，并计算增量 ILS和MET干预相对于安慰剂和彼此的医疗保健成本， 医疗保健行业的角度和社会的角度。